A disease that affects less than 200,000 people in the United States at any given time is classified as a rare disease. There are over 6,800 rare diseases, according to the National Human Genome Research Institute. Approximately 80% of rare diseases are believed to have a genetic origin.
The stock we are revisiting today is that of Rezolute Inc. (RZLT), a late-stage rare disease company focused on developing transformative therapies for rare diseases with serious unmet needs. Its lead drug candidate is Ersodetug, under development for treating hypoglycemia (low blood sugar levels) due to any congenital or acquired form of Hyperinsulinism, say, Tumour-related HI.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.